Melatonin and mammary pathological growth

Frontiers in Neuroendocrinology

Volumn 21, Issue 2, 2000, Pages 133-170

  Cos, Samuel ^a   Sánchez Barceló, Emilio J ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Breast cancer; Mammary cancer; MCF 7 cells; Melatonin; Pineal gland

Indexed keywords

MELATONIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CELL STRAIN MCF 7; CLINICAL TRIAL; HUMAN; NONHUMAN; PINEAL BODY; PRIORITY JOURNAL; REVIEW;

EID: 0342804465     PISSN: 00913022     EISSN: None     Source Type: Journal    
DOI: 10.1006/frne.1999.0194     Document Type: Article

References (181)

1. Adams D J, Edwards D P, McGuire W L. Hormone action in human breast cancer. McKems K W. Regulation of Gene Expression by Hormones. 1983;1-25 Plenum, New York.
2. Albini A, Graf J, Kitten G T, Kleinman H K, Martin G R, Veillette A, Lippman M E. 17β-Estradiol regulates and v-Ha-ras transfection constitutively enhances MCF-7 breast cancer cell interactions with basement membrane. Proc Natl Acad Sci USA. 83:1986;8182-8186.
3. Anisimov V N, Morozov V G, Kbavinson V Kh, Dilman V M. Comparison of the anti-tumor activity of extracts of the epiphysis and hypothalamus melatonin and sygethin in mice with transplanted mammary gland cancer. Vopr Onkol. 19:1973;99-101.
4. Anisimov V N, Kbavinson V Kh, Morozov V G. Twenty years of study on effects of pineal peptide preparation: Epithalamin in experimental gerontology and oncology. Ann NY Acad Sci. 719:1994;483-493.
5. Anton-Tay F, Martínez I, Tovar R, Benitez-King G. Modulation of the subcellular distribution of calmodulin by melatonin in MDCK cells. J Pineal Res. 24:1998;35-42.
6. Aubert C, Janiaud P, Lecalvez J. Effect of pinealectomy and melatonin on mammary tumor growth in Sprague-Dawley rats under different conditions of lighting. J Neural Transm. 47:1980;121-130.
7. Baldwin W S, Travlos G S, Risinger J I, Barrett J C. Melatonin does not inhibit estradiol-stimulated proliferation in MCF-7 and BG-1 cells. Carcinogenesis. 19:1998;1895-1900.
8. Bartsch C, Barstch H, Jain A K, Laumas K R, Wetterberg L. Urinary melatonin levels in human breast cancer patients. J Neural Transm. 52:1981;281-294.
9. Bartsch C, Barstch H, Fuchs U, Lippert T H, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. Cancer. 64:1989;426-433.
10. Bartsch C, Bartsch H, Lippert T H, Gupta D. Effect of the mammary carcinogen 7,12-dimethylbenz(a)anthracene on pineal melatonin biosynthesis, secretion and peripheral metabolism. Neuroendocrinology. 52:1990;538-544.
11. Bartsch C, Bartsch H, Bellman O, Lippert T H. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer. 67:1991;1681-1684.
12. Bartsch C, Bartsch H, Lippert T H. The pineal gland and cancer: Facts, hypotheses and perspectives. Cancer J. 5:1992;194-199.
13. Bartsch H, Bartsch C, Simon W E, Flehmig B, Ebels I, Lippert T H. Antitumor activity of the pineal gland: Effect of unidentified substances versus the effect of melatonin. Oncology. 49:1992;27-30.
14. Bartsch C, Barstch H, Lippert T H. Rationales to consider the use of melatonin as a chrono-oncotherapeutic drug. In Vivo. 9:1995;305-309.
15. Baum A, Mevissen M, Kamino K, Mohr U, Löscher W. A histopathological study on alterations in DMBA-induced mammary carcinogenesis in rats with 50 Hz muT magnetic field exposure. Carcinogenesis. 16:1995;119-125.
16. Becker-Andre M, Wiesenberg I, Schaeren-Wiemers N, Andre E, Missbach M, Saurat J H, Carlberg C. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem. 269:1994;28531-28534.
17. Benitez-King G, Huerto-Delgadillo L, Anton-Tay F. Melatonin effects on the cytoskeletal organization in MDCK and neuroblastoma NIE-115 cells. J Pineal Res. 9:1990;209-220.
18. Benitez-King G, Anton-Tay F. Calmodulin mediates melatonin-cytoskeletal effects. Experientia. 49:1993;635-641.
19. Blask D E. The pineal: An oncostatic gland? Reiter R J. The Pineal Gland. 1984;253-284 Raven Press, New York.
20. Blask D E. Melatonin in Oncology. Yu H-S, Reiter R J. Melatonin. Biosynthesis, Physiological Effects, and Clinical Applications. 1993;447-475 CRC Press, Boca Raton.
21. Blask D E, Hill S M. Effects of melatonin on cancer: Studies on MCF-7 human breast cancer cells in culture. J Neural Transm (Suppl). 21:1986;433-449.
22. Blask D E, Hill S M, Orstead K M, Massa J S. Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7,12-dimethyl-benz(a)anthracene (DMBA)-induced mammary tumorigenesis. J Neural Transm. 67:1986;125-138.
23. Blask D E, Hill S M. Melatonin and cancer: Basic and clinical aspects. Miles A, Philbrick D RS, Thompson C. Melatonin. Clinical Perspectives. 1988;128-173 Oxford Univ. Press, New York.
24. Blask, D, E, Cos, S, Hill, S, M, Burns, D, M, Lemus-Wilson, A, Pelletier, D, B, Liaw, L, Hill, A. Breast cancer, a target site for the oncostatic actions of pineal hormones. In: Reiter, R, J, Lukaszyk, A, Eds. Advances in Pineal Research: 4. London, Libbey, 1990: 267-274.
25. Blask D E, Pelletier D B, Hill S M, Lemus-Wilson A, Grosso D S, Wilson S T, Wise M E. Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: Potential involvement of antiestrogenic mechanism in vivo. J Cancer Res Clin Oncol. 117:1991;526-532.
26. Blask, D, E, Lemus-Wilson, A, M, Wilson, S, T, Cos, S. Neurohormonal modulation of cancer growth by pineal melatonin. In: Touitou, Y, Arendt, J, Pevet, P, Eds. Melatonin and the Pineal Gland: From Basic Science to Clinical Application. Holland, Elsevier Science, 1993: 303-310.
27. Blask D E, Wilson S T. Melatonin and oncostatic signal transduction: Evidence for a novel mechanism involving glutathione and nitric oxide. Moller M, Pévet P. Advances in Pineal Research: 8. 1994;465-471 Libbey, London.
28. Blask D E, Wilson S T, Zalatan F. Physiological melatonin inhibition of human breast cancer growth in vitro: Evidence for a glutathion-mediated pathway. Cancer Res. 57:1997;1909-1914.
29. Brainard G C, Kavet R, Kheifets L I. The relationship between electromagnetic field and light exposures to melatonin and breast cancer risk: A review of the relevant literature. J Pineal Res. 26:1999;65-100.
30. Burns J K. Administration of melatonin to non-human primates and to women with breast carcinoma. J Physiol. 229:1973;38P-39P.
31. Brooks S C, Locke E R, Soule H D. Estrogen receptor in a human breast tumor cell line (MCF-7) from breast carcinoma. J Biol Chem. 248:1973;6251-6256.
32. Chang N, Spaulding T S, Tseng M T. Inhibitory effects of superior cervical ganglionectomy on dimethyl-benz(a)anthracene-induced mammary tumors in the rat. J Pineal Res. 2:1985;331-340.
33. Chang N, Tseng M T, Spaulding T S. Induction and growth of mammary tumors after superior cervical ganglionectomy in sighted and blinded-anosmic rats. Life Sci. 38:1986;1821-1826.
34. Cohen M, Lippman M, Chabner B. Role of the pineal gland in aetiology and treatment of breast cancer. Lancet. 2:1978;814-816.
35. Cos S, Garijo F, Corral J, Mediavilla M D, Sánchez-Barceló E J. Histopathologic features of DMBA-induced mammary tumors in blind-underfed, blind-anosmic, and blind cold-exposed rats: Influence of the pineal gland. J Pineal Res. 6:1989;221-231.
36. Cos S, Blask D E. Effects of the pineal hormone melatonin on the anchorage-independent growth of human breast cancer cells (MCF-7) in a clonogenic culture system. Cancer Lett. 50:1990;115-119.
37. Cos S, Blask D E, Lemus-Wilson A, Hill A B. Effects of melatonin on the cell cycle kinetics and estrogen rescue of MCF-7 human breast cancer cells in culture. J Pineal Res. 10:1991;36-42.
38. Cos S, Blask D E. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J Pineal Res. 17:1994;25-32.
39. Cos S, Sánchez-Barceló E J. Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation. Cancer Lett. 84:1994;105-109.
40. Cos S, Sánchez-Barceló E J. Melatonin inhibition of MCF-7 human breast-cancer cells growth: Influence of cell proliferation rate. Cancer Lett. 93:1995;207-212.
41. Cos S, Recio J, Sánchez-Barceló E J. Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin. Life Sci. 58:1996;811-816.
42. Cos S, Fernández F, Sánchez-Barceló E J. Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. Life Sci. 58:1996;2447-2453.
43. Cos, S, Sánchez-Barceló, E, J. Melatonin reduces the invasion capacity of MCF-7 human breast cancer cells. In vitro studies. In: Webb, S, M, Puig-Domingo, M, Moller, M, Pévet, P, Eds. Pineal Update. From Molecular Mechanisms to Clinical Implications. New York, PJD, 1997: 377-383.
44. Cos S, Fernández R, Güézmes A, Sánchez-Barceló E J. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 58:1998;4383-4390.
45. Crespo D, Fernández-Viadero R, Verduga R, Ovejero V, Cos S. Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. J Pineal Res. 16:1994;215-222.
46. Danforth D N, Tamarkin L, Lippman M E. Melatonin increases oestrogen receptor binding activity of human breast cancer cells. Nature. 305:1983;323-325.
47. Danforth D N, Tamarkin L, Mulvihill J J, Bagley C S, Lippman M E. Plasma melatonin and the hormone-dependency of human breast cancer. J Clin Oncol. 3:1985;941-948.
48. DiBella L, Scalera G, Rossi M T. Perspectives in pineal function. Kappers J A, Pevet P. The Pineal Gland of Vertebrates Including Man, Progress in Brain Research. 1979;475-478 Oxford Univ. Press, New York.
49. Dickson C. Molecular aspects of mouse mammary tumor virus biology. Int Rev Cytol. 108:1987;119-147.
50. Dilman V M, Anisimov V N, Ostroumova M N, Morosov V G, Khavinson V Kh, Azorova M A. Study of anti-tumor effect of polypeptide pineal extract. Oncology. 36:1979;274-280.
51. Dogliotti L, Berruti A, Buniva T, Torta M, Bottini A, Tampellini M, Terzolo, Faggiuolo R, Angeli A. Melatonin and human cancer. J Steroid Biochem Mol Biol. 37:1990;983-987.
52. Eck M C, Yuan L, Duffy L, Ram P T, Ayettey S, Chen I, Cohn C S, Reed J C, Hill S M. A sequential treatment regimen with melatonin and all trans retinoic acid induces apoptosis in MCF-7 tumour cells. Br J Cancer. 77:1998;2129-2137.
53. Falkson G, Falkson H C, Steyn M E, Rapoport B L, Meyer B J. Plasma melatonin in patients with breast cancer. Oncology. 47:1990;401-405.
54. Frenkel K. Carcinogen mediated oxidant formation and oxidative DNA damage. Pharmacol Ther. 53:1992;127-166.
55. Glass J D, Lynch G R. Melatonin: identification of sites of antigonadal action in mouse brain. Science. 214:1981;821-823.
56. Hamilton T. Influence of environmental light and melatonin upon mammary tumor induction. Br J Surg. 56:1969;764-766.
57. Hardeland R, Reiter R J, Poeggeler B, Tan D X. The significance of the metabolism of the neurohormone melatonin: Antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev. 17:1993;347-357.
58. Harland J D, Liburdy R P. Environmental magnetic fields inhibit the antiproliferative action of tamoxifen and melatonin in a human breast cancer cell line. Bioelectromagnetics. 18:1997;555-562.
59. Hill S M, Blask D E. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) ib culture. Cancer Res. 48:1988;6121-6126.
60. Hill S M, Spriggs L L, Simon M A, Muraoka H, Blask D E. The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett. 64:1992;249-256.
61. Horwitz K B, McGuire W L. Estrogen control of progesterone receptor in human breast cancer: Correlations with nuclear processing of estrogen receptors. J Biol Chem. 253:1978;2223-2228.
62. Huerto-Delgadillo L, Anton-Tay F, Benitez-King G. Effects of melatonin on microtubule assembly depend on hormone concentration: Role of melatonin as a calmodulin antagonist. J Pineal Res. 17:1994;55-62.
63. Huggins C, Grand L C, Brillantes F P. Mammary cancer induced by a single feeding of polynuclear hydrocarbons and its suppression. Nature. 189:1961;204-207.
64. Ianas O, Olivescu R, Badescu I. Melatonin involvement in oxidative processes. Rom J Endocr. 29:1991;117-123.
65. Jakesz R, Smith C A, Aitken S, Huff K, Schuette W, Shackney S, Lippman M. Influence of cell proliferation and cell phase on expression of estrogen receptor in MCF-7 breast cancer cells. Cancer Res. 44:1984;619-625.
66. Karmali, R, A, Horrobin, D, F, Ghayur, T, Role of pineal gland in the aetiology and treatment of breast cancer, Lancet, 1978;, 2, 1002.
67. Kato M, Honma K I, Shigemitsu T, Shiga Y. Effects of exposure to circulatory to a circulatory polarized 50-Hz magnetic field on plasma and pineal melatonin levels in rats. Bioelectromagnetics. 14:1993;97-106.
68. Kojima T, Mochizuki C, Mitaka T, Mochizuki Y. Effects of melatonin on proliferation, oxidative stress and Cx32 gap junction protein expression in primary cultures of adult rat hepatocytes. Cell Struct Funct. 22:1997;347-356.
69. Kothari L S. Influence of chronic melatonin on 9,10-dimethyl-1,2-benzanthracene induced mammary tumors in female Holtzman rats exposed to continuous light. Oncology. 44:1987;64-66.
70. Kothari L S, Shah P N, Mhatre M C. Effect of continuous light on the incidence of 9,10-dimethyl-1,2-benzanthracene induced mammary tumors in female Holtzman rats. Cancer Lett. 16:1982;313-317.
71. Kothari L S, Shah P N, Mhatre M C. Pineal ablation in varying photoperiods and the incidence of 9,10-dimethyl-1,2-benzanthracene induced mammary cancer in rats. Cancer Lett. 22:1984;99-102.
72. Kothari L, Subramanian A. A possible modulatory influence of melatonin on representative phase I and phase II drug metabolizing enzymes in 9,10-dimethyl-1,2-benzanthracene induced rat mammary tumorigenesis. Anti-Cancer Drugs. 3:1992;623-628.
73. Kothari A, Borges A, Kothari L. Chemoprevention by melatonin and combined melatonin-tamoxifen therapy of second generation nitroso-methylurea-induced mammary tumors in rats. Eur J Cancer Prev. 4:1995;497-500.
74. Kothari A, Borges A, Ingle A, Kothari L. Combination of melatonin and tamoxifen as a chemoprophylaxis against N-nitroso-N-methylurea-induced rat mammary tumors. Cancer Lett. 111:1997;59-66.
75. L'Hermite-Balériaux M, Launoit Y. Is melatonin really an in vitro inhibitor of human breast cancer cell proliferation. In Vitro Cell Dev Biol. 28A:1992;583-584.
76. Lapin V. Effects of reserpine on the incidence of 9,10-dimethyl-1,2-benzanthracene induced tumors in pinealectomized and thymectomized rats. Oncology. 35:1978;132-135.
77. Lapin V, Ebels I. Effects of some low molecular weight sheep pineal fractions and melatonin on different tumours in rats and mice. Oncology. 33:1976;110-113.
78. Lapin V, Ebels I. The role of the pineal gland in neuroendocrine control mechanisms of neoplastic growth. J Neural Transm. 50:1981;275-282.
79. Leadem C A, Blask D E. Evidence for an inhibitory influence of the pineal on prolactin in female rat. Neuroendocrinology. 33:1981;268-275.
80. Lemus-Wilson A, Kelly P A, Blask D E. Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. Br J Cancer. 72:1995;1435-1440.
81. Lerner, A, B, Case, J, D, Takahashi, Y, Lee, T, H, Mori, W, Isolation of melatonin, the pineal gland factor that lightens melanocytes, J Am Chem Soc, 1958;, 80, 2587.
82. Lewy A J, Wehr T A, Goodwin F K, Newsome D A, Markey S P. Light suppresses melatonin secretion in humans. Science. 210:1980;1267-1269.
83. Liburdy R P, Sloma T R, Sokolic R, Yaswen P. ELF magnetic fields, breast cancer, and melatonin: 60 Hz fields block melatonin's oncostatic action on ER+ breast cancer cell proliferation. J Pineal Res. 14:1993;89-97.
84. Lissoni P, Barni S, Tancini G, Crispino S, Paolorossi F, Lucini V, Mariani M, Cattaneo G, Esposti D, Esposti G, Fraschini F. Clinical study of melatonin in untreatable advanced cancer patients. Tumori. 73:1987;475-480.
85. Lissoni P, Paolorossi F, Barni S, Tancini G, Crispino S, Rovelli F, Ferri L, Esposti G, Esposti D, Fraschini F. Correlation between changes in prolactin and melatonin serum levels after radical mastectomy. Tumori. 73:1987;263-267.
86. Lissoni P, Barni S, Crispino S, Tancini G, Fraschini F. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol. 25:1989;789-795.
87. Lissoni P, Brivio F, Barni S, Tancini G, Cattaneo G, Archili C, Conti A, Maestroni G JM. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension. Anticancer Res. 10:1990;1759-1762.
88. Lissoni P, Crispino S, Barni S, Sormani A, Brivio F, Pelizzoni F, Brenna A, Bratina G, Tancini G. Pineal gland and tumor cell kinetics: Serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. Oncology. 47:1990;275-277.
89. Lissoni P, Barni S, Cattaneo G, Tancini G, Esposti G, Esposti D, Fraschini F. Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology. 48:1991;448-450.
90. Lissoni P, Barni S, Ardizzoia A, Paolorossi F, Crispino S, Tancini G, Tisi E, Archili C, De Toma D, Pipino G, Conti A, Maestroni G JM. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology. 49:1992;336-339.
91. Lissoni P, Barni S, Brivio F, Rossini F, Fumagalli L, Tancini G. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study. J Biol Regul Homeost Agents. 9:1995;52-54.
92. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, Tancini G. Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer. 71:1995;854-856.
93. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, Maestroni G JM. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology. 53:1996;43-46.
94. Loomis D P, Savtz D A, Ananth C V. Breast cancer mortality among female electrical workers in the United States. J Natl Cancer Inst. 86:1994;921-925.
95. Löscher W, Wahnschaffe U, Mevissen M, Lerchl A, Stamm A. Effects of weak alternating magnetic fields on nocturnal melatonin production and mammary carcinogenesis in rats. Oncology. 51:1994;288-295.
96. Löscher W, Mevissen M, Häussler B. Seasonal influence on 7,12-dimethylbenz[a]anthracene-induced mammary carcinogenesis in Sprague-Dawley rats under controlled laboratory conditions. Pharmacol Toxicol. 81:1997;265-270.
97. Löscher W, Mevissen M, Lerchl A. Exposure of female rats to a 100-microT 50 Hz magnetic field does not induce consistent changes in nocturnal levels of melatonin. Radiat Res. 150:1998;557-567.
98. Maestroni G JM. The immunoneuroendocrine role of melatonin. J Pineal Res. 14:1993;1-10.
99. Maestroni G JM. T-helper-2 lymphocytes as a peripheral target of melatonin. J Pineal Res. 18:1995;84-89.
100. Maragos C, Wang J M, Hrabie J A, Oppenheim J J, Keefer L K. Nitric oxide/nucleophile complexes inhibit the in vitro proliferation of A375 melanoma cells via nitric oxide release. Cancer Res. 53:1993;564-568.
101. Martin J E, McKeel D W, Sattler C. Melatonin directly inhibits rat gonadotroph cells. Endocrinology. 110:1982;1079-1084.
102. Mavissen M, Häussler M, Lerchi A, Löscher W. Acceleration of mammary tumorigenesis by exposure of 7,12-dimethylbenz[a]anthracene-treated female rats in 50-Hz, 100-microT magnetic field: replication study. J Toxicol Environ Health. 53:1998;401-418.
103. Mediavilla M D, San Martin M, Sánchez-Barceló E J. Melatonin inhibits mammary gland development in female mice. J Pineal Res. 13:1992;13-19.
104. Mediavilla M D, Güezmes A, Ramos S, Kothari L, Garijo F, Sánchez-Barceló E J. Effects of melatonin on mammary gland lesions in transgenic mice overexpressing N-ras proto-oncogene. J Pineal Res. 22:1997;86-94.
105. Mediavilla M D, Cos S, Sánchez-Barceló E J. Melatonin increases p53 and p21waf1 expression in MCF-7 human breast cancer cells in vitro. Life Sci. 65:1999;415-420.
106. Medina D. The mammary gland: A unique organ for the study of development and tumorigenesis. J Mam Gland Biol Neoplasia. 1:1996;5-19.
107. Meites J. Relation of the neuroendocrine system to the development and growth of experimental mammary tumors. J Neural Transm. 48:1980;25-42.
108. Menéndez-Pelaez A, Poeggeler B, Reiter R J, Barlow-Walden L R, Pablos M I, Tan D X. Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence. J Cell Biochem. 53:1993;372-382.
109. Mevissen M, Lerchl A, Szamel M, Löscher W. Exposure of DMBA-treated rats in a 50-Hz, 50 μTesla magnetic field: Effects on mammary tumor growth, melatonin levels, and T lymphocyte activation. Carcinogenesis. 17:1996;903-910.
110. Mhatre M, Shah P, Juneja H. Effect of varying fotoperiods on mammary morphology, DNA synthesis and hormonal profile in female rats. J Natl Cancer Inst. 72:1984;1411-1416.
111. Molis T M, Walters M R, Hill S M. Melatonin modulation of estrogen receptor expression in MCF-7 human breast cancer cells. Int J Oncol. 3:1993;687-694.
112. Molis T M, Spriggs L L, Jupiter Y, Hill S M. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol. 8:1994;1681-1690.
113. Molis T M, Spriggs L L, Jupiter Y, Hill S M. Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer. J Pineal Res. 18:1995;93-103.
114. Morgan P J, Williams L M. The pars tuberalis of the pituitary: A gateway for neuroendocrine output. Rev Reprod. 1:1996;153-161.
115. Moulder J E. Power-frequency fields and cancer. Crit Rev Biomed Eng. 26:1998;1-116.
116. Nandi S, Guzman R C, Yang J. Hormones and mammary carcinogenesis in mice, rats and humans: A unifying hypothesis. Proc Natl Acad Sci USA. 92:1995;3650-3657.
117. Nelson R J, Demas G E. Seasonal changes in immune function. Q Rev Biol. 71:1996;511-548.
118. Olcese J. The neurobiology of magnetic field detection in rodents. Prog Neurobiol. 35:1990;325-330.
119. Olcese J, Reuss S. Magnetic field effects on pineal gland melatonin synthesis: Comparative studies on albino and pigmented rodents. Brain Res. 369:1986;365-368.
120. Osborne C K, Hobbs K, Clark G M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 45:1985;584-590.
121. Osborne C K, Hobbs K, Trent J M. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat. 9:1987;111-121.
122. Panzer A, Viljoen M. The validity of melatonin as an oncostatic agent. J Pineal Res. 22:1997;184-202.
123. Panzer A, Lottering M-L, Bianchi P, Glencross D K, Stark J H, Seegers C. Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells. Cancer Lett. 122:1998;17-23.
124. Papazisis K T, Kouretas D, Geromichalos G D, Sivridis E, Tsekreli O K, Dimitriadis K A, Kortsaris A H. Effects of melatonin on proliferation of cancer cell lines. J Pineal Res. 25:1998;211-218.
125. Pattengale P K, Stewart T, Leder A, Sinn E, Muller W, Tepler I, Schmidt E, Leder P. Animal models of human disease: Pathology and molecular biology of spontaneous neoplasmas occurring in transgenic mice carrying and expressing activated cellular oncogenes. Am J Pathol. 135:1989;39-61.
126. Pelletier D B, Hill S M, Blask D E. Inhibition of N-methylnitrosurea (NMU)-induced mammary carcinogenesis by melatonin. Soc Neurosci. 13:1987;450.
127. Pieri C, Marra M, Moroni F, Recchioni F, Marcheselli F. Melatonin: A peroxyl radical scavenger more effective that vitamin E. Life Sci. 15:1994;PL271-PL276.
128. Poeggeler B, Reiter R J, Tan D X, Chen L D, Manchester L C. Melatonin, hydroxyl radical-mediated oxidative damage and aging: a hypothesis. J Pineal Res. 14:1993;151-168.
129. Praast G, Bartsch C, Bartsch H, Mecke D, Lippert T H. Hepatic hydroxylation of melatonin in the rat is induced by phenobarbital and 7,12-dimethylbenz[a]anthracene - Implications for cancer etiology. Experientia. 51:1995;349-355.
130. Rato A G, Pedrero J G, Martinez M A, del Rio B, Lazo P S, Ramos S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J. 13:1999;857-868.
131. Recio J, Cardinali D P, Sanchez-Barcelo E J. 2-[125I]iodomelatonin binding sites in murine mammary tissue. Biol Signals. 3:1994;85-90.
132. 125I]iodomelatonin binding sites in murine mammary tissue. J Pineal Res. 16:1994;10-17.
133. Reiter R J. The pineal gland and its hormones in the control of reproduction in mammals. Endocr Rev. 1:1980;109-131.
134. Reiter R J. Pineal gland, cellular proliferation and neoplastic growth: An historical account. Gupta D, Attanasio A, Reiter R J. The Pineal Gland and Cancer. 1988;41-64 Brain Research Promotion, Tübingen.
135. Reiter R J. Electromagnetic fields and melatonin production. Biomed Pharmacother. 47:1993;439-444.
136. Reiter R J. Interactions of the pineal hormone melatonin with oxygen-centered free radicals: a brief review. Braz J Med Biol Res. 26:1993;1141-1155.
137. Reiter R J. Functional pleiotropy of the neurohormone melatonin: Antioxidant protection and neuroendocrine regulation. Front Neuroendocrinol. 16:1995;383-415.
138. Reiter R J, Klein D C. Preliminary observations on the reproductive effects of the pineal gland in blinded anosmic male rats. J Reprod Fertil. 19:1969;563-565.
139. Reiter R J, Richardson B A. Magnetic field effects on pineal indoleamine metabolism and possible biological consequences. FASEB J. 6:1992;2283-2287.
140. Reiter R J, Poeggeler B, Tan D X, Chen L D, Manchester L C, Guerrero J M. Antioxidant capacity of melatonin: A novel action not requiring a receptor. Neuroendocrinol Lett. 15:1993;103-116.
141. Reiter R J, Tan D X, Poeggeler B, Chen L D, Menéndez-Pelaez A. Melatonin, free radicals and cancer initiation. Maestroni G JM, Conti A, Reiter R J. Advances in Pineal Research: 7. 1994;211-228 Libbey, London.
142. Reiter R J, Melchiorri D, Sewerynek E, Poeggeler B, Barlow-Walden L, Chuang J, Ortiz G G, Acuña-Castroviejo D. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res. 18:1995;1-11.
143. Relkin, R. The pineal and human disease. In: Relkin, R, Ed. Annual Research Reviews. The Pineal. Lancaster, Lundsdale House, Hornby, 1976: 76-79.
144. Russo I H, Russo J. Developmental stage of the rat mammary gland as determinant of its susceptibility to 7,12-dimethyl-benz(a)anthracene. J Natl Cancer Inst. 61:1978;1439-1449.
145. Russo J, Gusterson B A, Rogers A E, Russo I H, Wellings S R, Van Zwieten M J. Comparative study of human and rat mammary tumorigenesis. Lab Invest. 62:1990;1-32.
146. Russo I H, Russo J. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect. 104:1996;938-967.
147. Russo I H, Russo J. Role of hormones in mammary cancer initiation and progression. J Mam Gland Biol Neoplasia. 3:1998;49-61.
148. Sánchez-Barceló E J, Mediavilla M D, Sánchez-Criado J E, Cos S, Cortines M DG. Antigonadal actions of olfactory and light deprivation. I. Effects of blindness combined with olfactory bulb deafferentation, transection of vomeronasal nerves, or bulbectomy. J Pineal Res. 2:1985;177-190.
149. Sánchez-Barceló E J, Cos S, Mediavilla M D. Cold exposure as a potentiating factor of pineal actions in nonhibernating mammals. Cryobiology. 23:1986;72-80.
150. Sánchez-Barceló E J, Cos S, Mediavilla M D. Influence of pineal gland function on the initiation and growth of hormone-dependent breast tumors. Possible mechanisms. Gupta D, Attanasio A, Reiter R J. The Pineal Gland and Cancer. 1988;221-232 Brain Research Promotion, Tübingen.
151. Sánchez-Barceló E J, Mediavilla M D, Tucker H A. Influence of melatonin on mammary growth: In vivo and in vitro studies. Proc Soc Exp Biol Med. 194:1990;103-107.
152. Sánchez-Barceló E J, Mediavilla M D, Zinn S A, Buchanan B A, Chapin L T, Tucker H A. Melatonin suppression of mammary growth in heifers. Biol Reprod. 44:1991;875-879.
153. Seshadri R, Subramanian A, Kothari L S. Effect of neonatal pineal ablation on estradiol receptors in mammary glands of rats housed under varying photoperiods. Ind J Exp Biol. 30:1992;162-164.
154. Shah P N, Mhatre M C, Kothari L S. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res. 44:1984;3403-3407.
155. Shellard S A, Whelan R DH, Hill B T. Growth inhibitory and cytotoxic effects of melatonin and its metabolites on human tumour cell lines in vitro. Br J Cancer. 60:1989;288-290.
156. Skene D J, Bojkowski C J, Currie J E, Wright J, Boulter P S, Arendt J. 6-sulphatoxymelatonin production in breast cancer patients. J Pineal Res. 8:1990;269-276.
157. Sommers C L, Byers S W, Thompson E W, Torri J A, Gelmann E P. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat. 31:1994;325-335.
158. Sorrentino S, Reiter R J, Schalch D S, Donofrio R J. Interactions of the pineal gland, blinding, and underfeeding on reproductive organ size and radioimmunoassayable growth hormone. Neuroendocrinology. 7:1971;105-115.
159. Sorrentino S, Reiter R J, Schalch D S, Donofrio R J. Role of the pineal gland in growth restraint of adult male rats by light and smell deprivation. Neuroendocrinology. 8:1971;116-124.
160. Soule H D, Vazquez J, Long A, Albert S, Brennan M J. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 51:1973;1409-1412.
161. Stankov, B, Lucini, V, Scaglione, F, Cozzi, B, Righi, M, Canti, G, Demartini, G, Fraschini, F. 2-125I-iodomelatonin binding in normal and neoplastic tissues. In: Fraschini, F, Reiter, R, J, Eds. Role of Melatonin and Pineal Peptides in Neuroimmunomodulation. New York, Plenum, 1991: 117-127.
162. Steinhilber D, Brungs M, Werz O, Wiesenberg I, Danielsson C, Kahlen J P, Nayeri S, Schrader M, Carlberg C. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J Biol Chem. 270:1995;7037-7040.
163. Subramanian A, Kothari L S. Melatonin and DMBA-induced rat mammary gland carcinogenesis: Initiation and promotion phases. European Pineal Study Group. 1990;159.
164. Subramanian A, Kothari L S. Melatonin, a suppressor of spontaneous murine mammary tumors. J Pineal Res. 10:1991;136-140.
165. Subramanian A, Kothari L S. Suppressive effect by melatonin on different phases of 9,10-dimethyl-1,2-benzanthracene (DMBA)-induced rat mammary gland carcinogenesis. Anti-Cancer Drugs. 2:1991;297-303.
166. Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, Chabner B. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethyl-benz(a)anthracene-induced mammary tumors in the rat. Cancer Res. 41:1981;4432-4436.
167. Tamarkin L, Danforth D N, Lichter A, DeMoss E, Cohen M, Chabner B, Lippman M. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science. 216:1982;1003-1005.
168. Tan D X, Poeggeler B, Reiter R J, Chen L D, Chen S, Manchester L C, Barlow-Walden L R. The pineal hormone melatonin inhibits DNA adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett. 70:1993;65-71.
169. Tan D X, Reiter R J, Chen L D, Poeggeler B, Manchester L C, Barlow-Walden L R. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis. 15:1994;215-218.
170. Trosko J E, Chang C C, Madhukar B V, Klaunig J E. Chemical, oncogene and growth factor inhibition gap junctional intercellular communication: An integrative hypothesis of carcinogenesis. Pathobiology. 58:1990;265-278.
171. Tynes T, Hannevik M, Andersen A, Vistnes A I, Haldorsen T. Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Causes Control. 7:1996;197-204.
172. Ubeda A, Trillo M A, House D E, Blackman C F. Melatonin enhances junctional transfer in normal C3H/10T1/1 cells. Cancer Lett. 91:1995;241-245.
173. Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev. 78:1998;687-721.
174. Vaticon D, Fernández-Galaz C, Esquifino A, Tejero A, Aguilar E. Effect of constant light on prolactin secretion in adult female rats. Horm Res. 12:1980;277-288.
175. Viviani S, Negretti E, Orazi A, Sozzi G, Santoro A, Lissoni P, Esposti G, Fraschini F. Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy. J Pineal Res. 8:1990;347-354.
176. Watanabe Y, Sawada N, Isomura H, Satoh H, Hirata K, Mori M. Estrogen-depleted condition induces apoptosis of rat mammary cancer cells after entering the S-phase of the cell cycle. Cell Struct Funct. 20:1995;125-132.
177. Welsch C W. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: A review and tribute to Charles Brenton Huggins. Cancer Res. 45:1985;3415-3442.
178. Welsch C W, Nagasawa H. Prolactin and murine mammary tumorigenesis: A review. Cancer Res. 37:1977;951-963.
179. Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol. 72:1994;537-545.
180. Wrba H, Halberg F, Dutter A. Melatonin circadian-stage-dependently delays breast tumor development in mice injected daily for several months. Chronobiology. 13:1986;123-128.
181. Yagasaki R, Noguchi M, Minami M, Earashi M. Clinical significance of E-cadherin and vimentin co-expression in breast cancer. Int J Oncol. 9:1996;755-761.